The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program.
CA19.9
GICA
biomarkers
early detection
follow-up
pancreatic cancer
pancreatic cysts
pancreatic lesions
surgical intervention
surveillance
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
25
02
2023
accepted:
05
05
2023
medline:
12
9
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate the role of CA19.9 monitoring for early detection and management in a cyst surveillance population. The PACYFIC-registry is a prospective collaboration that investigates the yield of pancreatic cyst surveillance performed at the discretion of the treating physician. We included participants for whom at least one serum CA19.9 value was determined by a minimum follow-up of 12 months. Of 1865 PACYFIC participants, 685 met the inclusion criteria for this study (mean age 67 years, SD 10; 61% female). During a median follow-up of 25 months (IQR 24, 1966 visits), 29 participants developed high-grade dysplasia (HGD) or pancreatic cancer. At baseline, CA19.9 ranged from 1 to 591 kU/L (median 10 kU/L [IQR 14]), and was elevated (≥37 kU/L) in 64 participants (9%). During 191 of 1966 visits (10%), an elevated CA19.9 was detected, and these visits more often led to an intensified follow-up (42%) than those without an elevated CA19.9 (27%; p < 0.001). An elevated CA19.9 was the sole reason for surgery in five participants with benign disease (10%). The baseline CA19.9 value was (as continuous or dichotomous variable at the 37 kU/L threshold) not independently associated with HGD or pancreatic cancer development, whilst a CA19.9 of ≥ 133 kU/L was (HR 3.8, 95% CI 1.1-13, p = 0.03). In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false-positive values. The role of CA19.9 monitoring should be critically appraised prior to implementation in surveillance programs and guidelines.
Sections du résumé
BACKGROUND
Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate the role of CA19.9 monitoring for early detection and management in a cyst surveillance population.
METHODS
The PACYFIC-registry is a prospective collaboration that investigates the yield of pancreatic cyst surveillance performed at the discretion of the treating physician. We included participants for whom at least one serum CA19.9 value was determined by a minimum follow-up of 12 months.
RESULTS
Of 1865 PACYFIC participants, 685 met the inclusion criteria for this study (mean age 67 years, SD 10; 61% female). During a median follow-up of 25 months (IQR 24, 1966 visits), 29 participants developed high-grade dysplasia (HGD) or pancreatic cancer. At baseline, CA19.9 ranged from 1 to 591 kU/L (median 10 kU/L [IQR 14]), and was elevated (≥37 kU/L) in 64 participants (9%). During 191 of 1966 visits (10%), an elevated CA19.9 was detected, and these visits more often led to an intensified follow-up (42%) than those without an elevated CA19.9 (27%; p < 0.001). An elevated CA19.9 was the sole reason for surgery in five participants with benign disease (10%). The baseline CA19.9 value was (as continuous or dichotomous variable at the 37 kU/L threshold) not independently associated with HGD or pancreatic cancer development, whilst a CA19.9 of ≥ 133 kU/L was (HR 3.8, 95% CI 1.1-13, p = 0.03).
CONCLUSIONS
In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false-positive values. The role of CA19.9 monitoring should be critically appraised prior to implementation in surveillance programs and guidelines.
Identifiants
pubmed: 37435855
doi: 10.1002/ueg2.12422
pmc: PMC10493362
doi:
Substances chimiques
CA-19-9 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-611Informations de copyright
© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Am J Surg. 2009 Sep;198(3):333-9
pubmed: 19375064
Eur Surg Res. 2021;62(2):80-87
pubmed: 33827087
Sci Rep. 2020 Jun 1;10(1):8820
pubmed: 32483216
United European Gastroenterol J. 2023 Sep;11(7):601-611
pubmed: 37435855
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Pancreatology. 2020 Apr;20(3):505-510
pubmed: 31948794
Biomarkers. 2020 Mar;25(2):186-193
pubmed: 32009482
Eur J Surg Oncol. 2022 Jun;48(6):1293-1299
pubmed: 34887167
Ann Surg. 2017 Dec;266(6):1062-1068
pubmed: 27607098
J Hepatobiliary Pancreat Sci. 2015 Sep;22(9):699-707
pubmed: 26178866
Gastrointest Endosc. 2022 Nov;96(5):801-813.e2
pubmed: 35537661
Eur J Surg Oncol. 2015 Feb;41(2):265-9
pubmed: 25266999
Diagnostics (Basel). 2020 Nov 17;10(11):
pubmed: 33213103
Gut. 2018 May;67(5):789-804
pubmed: 29574408
Gastroenterology. 2020 Jan;158(1):226-237.e5
pubmed: 31473224
Surg Oncol. 2021 Sep;38:101582
pubmed: 33892432
BMC Cancer. 2021 May 7;21(1):517
pubmed: 33962560
Pancreatology. 2020 Jun;20(4):729-735
pubmed: 32332003
Gut. 2013 Mar;62(3):339-47
pubmed: 23135763
Fam Cancer. 2020 Jul;19(3):247-258
pubmed: 32193697
Surg Oncol. 2021 Sep;38:101573
pubmed: 33857838
Biomed Rep. 2015 Jan;3(1):43-50
pubmed: 25469245
Med J Malaysia. 2003 Dec;58(5):667-72
pubmed: 15190651
BMC Surg. 2019 Aug 22;19(1):115
pubmed: 31438917
Gastroenterology. 2021 Mar;160(4):1373-1383.e6
pubmed: 33333055
World J Gastrointest Surg. 2020 Dec 27;12(12):468-490
pubmed: 33437400